SPINELLA, AMELIA
 Distribuzione geografica
Continente #
NA - Nord America 10.724
AS - Asia 6.113
EU - Europa 4.589
SA - Sud America 843
Continente sconosciuto - Info sul continente non disponibili 225
AF - Africa 159
OC - Oceania 24
Totale 22.677
Nazione #
US - Stati Uniti d'America 10.410
SG - Singapore 1.826
CN - Cina 1.486
IT - Italia 1.389
GB - Regno Unito 940
HK - Hong Kong 678
BR - Brasile 638
VN - Vietnam 632
SE - Svezia 498
BD - Bangladesh 426
DE - Germania 412
FI - Finlandia 259
FR - Francia 255
RU - Federazione Russa 241
KR - Corea 216
IN - India 205
CA - Canada 170
ID - Indonesia 138
TR - Turchia 123
UA - Ucraina 101
MX - Messico 82
AR - Argentina 76
BG - Bulgaria 76
NL - Olanda 76
JP - Giappone 67
ES - Italia 63
ZA - Sudafrica 54
PL - Polonia 51
PK - Pakistan 44
IQ - Iraq 38
AT - Austria 35
CO - Colombia 33
MY - Malesia 33
IE - Irlanda 29
AE - Emirati Arabi Uniti 25
MA - Marocco 25
LT - Lituania 24
CL - Cile 23
AU - Australia 22
CZ - Repubblica Ceca 21
BE - Belgio 20
EC - Ecuador 20
EG - Egitto 19
VE - Venezuela 19
RO - Romania 18
SA - Arabia Saudita 16
IR - Iran 15
TN - Tunisia 15
NP - Nepal 13
PE - Perù 13
UZ - Uzbekistan 13
JO - Giordania 12
TW - Taiwan 12
AL - Albania 11
CR - Costa Rica 11
KE - Kenya 11
AZ - Azerbaigian 10
PH - Filippine 10
TH - Thailandia 10
EU - Europa 8
IL - Israele 8
OM - Oman 8
PT - Portogallo 8
PY - Paraguay 8
GR - Grecia 7
HN - Honduras 7
NG - Nigeria 7
PS - Palestinian Territory 7
BY - Bielorussia 6
BZ - Belize 6
DK - Danimarca 6
DZ - Algeria 6
GT - Guatemala 6
HU - Ungheria 6
RS - Serbia 6
UY - Uruguay 6
BH - Bahrain 5
CH - Svizzera 5
DO - Repubblica Dominicana 5
JM - Giamaica 5
KG - Kirghizistan 5
SY - Repubblica araba siriana 5
EE - Estonia 4
ET - Etiopia 4
HR - Croazia 4
LU - Lussemburgo 4
SK - Slovacchia (Repubblica Slovacca) 4
TT - Trinidad e Tobago 4
AO - Angola 3
BB - Barbados 3
BO - Bolivia 3
GE - Georgia 3
KZ - Kazakistan 3
LA - Repubblica Popolare Democratica del Laos 3
MD - Moldavia 3
MV - Maldive 3
PA - Panama 3
PR - Porto Rico 3
SV - El Salvador 3
A2 - ???statistics.table.value.countryCode.A2??? 2
Totale 22.413
Città #
Santa Clara 1.210
Ashburn 1.136
Singapore 1.133
San Jose 753
Fairfield 670
Hong Kong 668
Chandler 592
Council Bluffs 528
Southend 470
Hefei 439
Woodbridge 321
Houston 316
Seattle 267
Nyköping 266
London 252
Beijing 236
Wilmington 223
New York 208
Los Angeles 204
Cambridge 200
Ho Chi Minh City 197
Helsinki 192
Seoul 191
The Dalles 166
Hanoi 163
Milan 145
Jacksonville 144
Ann Arbor 140
Chicago 140
Dearborn 133
San Diego 124
Bologna 116
Modena 116
Jakarta 111
Lauterbourg 85
Buffalo 83
Sofia 74
Princeton 73
Munich 70
Bremen 69
Shanghai 69
São Paulo 69
Orem 64
Atlanta 63
Dallas 62
Moscow 59
Frankfurt am Main 53
Izmir 51
Tokyo 51
Rome 47
Warsaw 42
Columbus 40
Salt Lake City 40
Denver 39
Montreal 39
Parma 37
Naples 36
Toronto 36
Florence 35
Johannesburg 35
Mexico City 33
Redwood City 32
Boardman 31
Phoenix 31
Poplar 30
Chennai 29
Reggio Emilia 29
Turku 29
Eugene 28
Guangzhou 28
Haiphong 28
New Delhi 28
Stockholm 28
Da Nang 26
Amsterdam 25
Ovada 25
Kent 24
Lappeenranta 24
Delhi 23
Mumbai 22
Ottawa 22
Nuremberg 21
Palermo 21
Redondo Beach 21
Paris 20
Portsmouth 20
Hillsboro 19
Rio de Janeiro 19
San Francisco 19
Brooklyn 18
Brussels 18
Philadelphia 18
Ankara 17
Dublin 17
Falls Church 17
Elk Grove Village 16
Tampa 16
Turin 16
Vancouver 16
Boston 15
Totale 14.510
Nome #
Systemic sclerosis progression INvestiGation (SPRING) Italian registry: Demographic and clinico-serological features of the scleroderma spectrum 431
Systemic sclerosis evolution of disease pathomorphosis and survival. Our experience on Italian patients' population and review of the literature 362
COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series 361
Cryoglobulin evaluation: analysis of intra-laboratory and inter-laboratory variability 352
Established coronary artery disease in systemic sclerosis compared to type 2 diabetic female patients: a cross-sectional study 350
Cardiac involvement in systemic sclerosis: identification of high-risk patient profiles in different patterns of clinical presentation 349
Elevated Troponin Serum Levels in Adult Onset Still's Disease 344
Cardio-pulmonary disease management in patients with systemic sclerosis: cardio-rheumatology clinic and patient care standardisation proposal 343
Efficacy of Belimumab for active lupus nephritis in a young Hispanic woman intolerant to standard treatment: a case report 333
Acute exacerbation of interstitial lung diseases secondary to systemic rheumatic diseases: A prospective study and review of the literature 332
Serum 25-OH vitamin D levels in systemic sclerosis: analysis of 140 patients and review of the literature 330
Unusual association between Budd–Chiari syndrome secondary to antiphospholipid syndrome and relapsing polychondritis: a case report and review of the literature 322
Ultrasonography involvement of carotid, upper and lower limb arteries in a large cohort of systemic sclerosis patients 320
The discrepancy between clinical and ultrasonographic remission in rheumatoid arthritis is not related to therapy or autoantibody status. 318
Long-term treatment with rituximab in interstitial lung disease related to systemic sclerosis: our clinical experience 312
Large Vessel Vasculitis Occurring in Rheumatoid Arthritis Patient under Anti-TNF Therapy 304
CLINICAL AND PATHOLOGICAL FEATURES OF BREAST CANCER IN PATIENTS WITH SYSTEMIC SCLEROSIS: PRELIMINARY DATA FROM THE SCLERO-BREAST STUDY 296
Management of cardiopulmonary disease in patients with systemic sclerosis: cardiorheumatology clinic and patient care standardization proposal 285
UNCLASSIFIABLE INTERSTITIAL LUNG DISEASE OR UNDIFFERENTIATED CONNECTIVE TISSUE DISEASE? A CHALLENGING DIFFERENTIAL DIAGNOSIS 279
Advanced oxidation protein products in serum of patients with systemic sclerosis: a possible indicator of clinical evolution 274
Beyond cat scratch disease: a case report of bartonella infection mimicking vasculitic disorder 273
Use of Neem oil and Hypericum perforatum for treatment of calcinosis-related skin ulcers in systemic sclerosis 267
The safety of iloprost in systemic sclerosis in a real-life experience 264
Photobiomodulation Therapy: A New Light in the Treatment of Systemic Sclerosis Skin Ulcers 264
Autologous Fat Grafting for the Oral and Digital Complications of Systemic Sclerosis: Results of a Prospective Study 262
INTERSTITIAL LUNG DISEASE IS ASSOCIATED TO INFECTIONS OF LOWER RESPIRATORY TRACT IN IMMUNOCOMPROMISED RHEUMATOID ARTHRITIS PATIENTS 257
Clinical and Pathological Features of Breast Cancer in Systemic Sclerosis: Results from the Sclero-Breast Study 257
Assessing hand grasp in patients with systemic sclerosis using the 16-grasp test: Preliminary results from a multidisciplinary study group 255
The prevalence of asymptomatic early sacroiliitis in Crohn’s disease patients: The single experience of an Italian tertiary care centre 250
Autologous fat grafting in the treatment of a scleroderma stump-skin ulcer: a case report 244
The profiling of axial spondyloarthritis patient candidate to a biologic therapy: Consensus from a Delphi-panel of Italian experts 243
Procedural pain management in the treatment of scleroderma digital ulcers 236
AB0611 STRAIN ANALYSIS OF THE RIGHT VENTRICLE USING 2D-SPECKLE TRACKING ECHOCARDIOGRAPHY IN A COHORT OF PATIENTS WITH SYSTEMIC SCLEROSIS 234
DANCE CLASS DEDICATED TO SCLERODERMA PATIENTS: JOINT EVALUATION, FUNCTIONAL AND QUALITY OF LIFE BEFORE AND AFTER TREATMENT – CLINICAL TRIAL 233
NATURAL HISTORY OF CRYOGLOBULINEMIA FROM 2000 TO 2018 FROM THE LABORATORY POINT OF VIEW: AN ANALYSIS OF CRYOGLOBULIN CHARACTERISTICS IN A SINGLE CENTER. 232
PREVALENCE OF ULTRASOUND ABNORMALITIES IN PATIENTS WITH PSORIATIC ARTHRITIS IN A CLINICAL PHASE OF MINIMAL DISEASE ACTIVITY UNDER ANTI-TNF TREATMENT 229
Thu0349 autologous fat grafting in the treatment of patients with systemic sclerosis: current experience and future prospects 226
Invited Response on: Comments on "Autologous Fat Grafting for the Oral and Digital Complications of Systemic Sclerosis: Results of a Prospective Study" 225
SEVERE VITAMIN D DEFICIENCY IN SYSTEMIC SCLEROSIS 224
Peripheral Microangiopathy Changes in Pulmonary Arterial Hypertension Related to Systemic Sclerosis: Data From a Multicenter Observational Study 222
COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study 222
Erratum: Acute exacerbation of interstitial lung diseases secondary to systemic rheumatic diseases: A prospective study and review of the literature (Journal of Thoracic Disease (2019) 11 (1621-1628) DOI: 10.21037/jtd.2019.03.28) 221
DIGITAL NECROSIS IN SYSTEMIC SCLEROSIS NOT ONLY A MICROVASCULAR DISEASE: A CASE REPORT 220
AB0645 CANNABINOIDS IN THE TREATMENT OF PAIN RELATED TO SYSTEMIC SCLEROSIS SKIN ULCERS: OUR EXPERIENCE 214
Promising use of filgotinib in patients affected by systemic sclerosis: Preliminary data from a case series of 5 patients 214
The predictive role of the TAPSE/sPAP ratio for cardiovascular events and mortality in systemic sclerosis with pulmonary hypertension 212
AB0724 Cardio-pulmonary disease management in patients with systemic sclerosis: cardio-rheumatology clinic and patient care standardisation proposal 212
Altered pathways of keratinization, extracellular matrix generation, angiogenesis, and stromal stem cells proliferation in patients with systemic sclerosis 210
COVID-19 in Italian patients with rheumatic autoimmune systemic diseases 209
Pulmonary arterial hypertension: Guidelines and unmet clinical needs 208
Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients’ subgroups 208
Molecular Pathways of Breast Cancer in Systemic Sclerosis: Exploratory Immunohistochemical Analysis from the Sclero-Breast Study 206
Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments 206
One-year clinical experience on the use of Nintedanib in Systemic Sclerosis 205
Management of Systemic Sclerosis Patients in the COVID-19 Era: The Experience of an Expert Specialist Reference Center 205
AB0760 Advanced oxidation protein products in serum of patients with systemic sclerosis: a possible indicator of clinical evolution 204
ORAL MANIFESTATIONS IN SYSTEMICSCLEROSIS: CLINICAL EVALUATION OF APERSONAL CASE SERIES OF 13 SCLERODERMAPATIENTS 200
Living with arthritis: a “training camp” for coping with stressful events? A survey on resilience of arthritis patients following the COVID-19 pandemic 200
Systemic sclerosis cutaneous expression: Management of skin fibrosis and digital ulcers 198
Impegno cardiaco nella sclerosi sistemica 191
AB0212 LONG-TERM TREATMENT WITH RITUXIMAB IN SYSTEMIC SCLEROSISMANAGEMENT: AN OVERVIEW OF THE CLINICAL EXPERIENCE FROM A REAL-LIFE SETTING 187
From Localized Scleroderma to Systemic Sclerosis: Coexistence or Possible Evolution 186
EFFICACY OF CERTOLIZUMAB PEGOL FOR DISEASE CONTROL OF PATIENTS AFFECTED BY ENTEROPATHIC SPONDYLARTHRITIS FOLLOWED BY THE JOINT GASTRO-RHEUMATOLOGICAL CLINIC 182
THU0600 a case of systemic sclerosis complicated by renal crisis: potential etiopathogenetic role of cytomegalovirus and treatment 181
Cryofibrinogen: A possibile risk factor in systemic sclerosis 180
A CALL FOR A COMPREHENSIVE ROLE DEFINITION OF THE STUDY COORDINATOR IN RHEUMATOLOGICAL CLINICAL STUDIES 179
Cryoproteinemia: new frontiers for clinicians and the laboratory 178
A New Promising Role for Selexipag in the Treatment of Scleroderma Vasculopathy: Preliminary Results From a Third Level Italian Scleroderma Center 177
Sex-related Differences in Systemic Sclerosis: A Multicenter Cross-sectional Study From the National Registry of the Italian Society for Rheumatology 175
THE PREDICTIVE ROLE OF THE TAPSE/sPAP RATIO FOR CARDIOVASCULAR EVENTS AND MORTALITY IN SYSTEMIC SCLEROSIS COMPLICATED BY PULMONARY HYPERTENSION 174
IS THERE A DISSOCIATION BETWEEN CLINICAL REMISSION AND ULTRASONOGRAPHIC ASSESSMENT IN RHEUMATOID ARTHRITIS? 173
ACCERTAMENTO DELLA DISABILITÀ NELLE MALATTIE REUMATOLOGICHE (EX L.R. N.4 DEL 19 FEBBRAIO 2008) PROPOSTA DI PROTOCOLLO ORGANIZZATIVO 170
POS0837 THE USE OF CANNABIDIOL IN THE TREATMENT OF PAIN RELATED TO SCLERODERMA DIGITAL ULCERS 170
Role of COVID-19 in the progression of scleroderma interstitial lung disease and new onset pulmonary hypertension: a challenging case report. 169
Organic-inorganic materials through first simultaneous frontal polymerization and frontal geopolymerization 166
PROBABILITÀ DI SIEROCONVERSIONE DEL TEST QUANTIFERON DURANTE LA TERAPIA BIOTECNOLOGICA: DATI PRELIMINARI DI UNO STUDIO RETROSPETTIVO CONDOTTO PRESSO L’ARTHRITIS CLINIC DELL’AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO DI MODENA 165
Letters to the Editors 165
Covid-19 vaccine hesitancy in systemic sclerosis 163
Long-term retention rate, adverse event temporal patterns and rescue treatment strategies of mycophenolate mofetil in systemic sclerosis: insights from real-life 159
SAT0285 EVALUATION OF CHRONIC PAIN IN PATIENTS WITH SYSTEMIC SCLEROSIS COMPARED TO THOSE WITH CHRONIC HEADACHE AND RHEUMATOID ARTHRITIS 159
Resilience of systemic sclerosis patients following the first COVID-19 wave in Italy 158
Real life use of prostacyclin analog (Iloprost), a multi-centric survey data from the scleroderma study group Emilia Romagna (Sclero-RER) and review of the literature 156
Erratum: Unusual association between Budd-Chiari syndrome secondary to antiphospholipid syndrome and relapsing polychondritis: A case report and review of the literature (Clinical Rheumatology (2013) 32 (905-907) DOI: 10.1007/s10067-013-2229-z) 156
JANUS KINASES INHIBITORS IN CLINICAL PRACTICE IN ITALY. RESULTS FROM A SINGLE CENTER EXPERIENCE 156
Secondary cryofibrinogenemia is related to more severe microangiopathic involvement in systemic sclerosis: results from a retrospective observational study. 156
Secondary cryofbrinogenemia is related to more severe microangiopathic involvement in systemic sclerosis: results from a retrospective observational study 147
FRI0442 Long-term treatment with rituximab in interstitial lung disease related to systemic sclerosis: our clinical experience 146
MYCOPHENOLATE MOFETIL TREATMENT REDUCES THE RISK OF TREATMENT ESCALATION DUE TO VASCULAR COMPLICATIONS IN LIMITED CUTANEOUS SYSTEMIC SCLEROSIS: EMULATION OF A TARGET TRIAL FROM ITALIAN RHEUMATOLOGY SOCIETY SPRING REGISTRY 142
Erratum: From Localized Scleroderma to Systemic Sclerosis: Coexistence or Possible Evolution (Dermatology Research and Practice (2018) 2018 (1284687) DOI: 10.1155/2018/1284687) 141
Clinical and ultrasonographic predictors of disease activity after TNF-α inhibitor spacing in patients with psoriatic arthritis 139
BMP-4 and fetuin A in systemic sclerosis patients with or without calcinosis 137
L’IPERTENSIONE POLMONARE: DALLE NUOVE LINEE GUIDA ALLA PRATICA CLINICA 136
Real-life efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre study 135
Infections of scleroderma digital ulcers: A single center cohort retrospective study 126
OP0063 QUANTITATIVE COMPUTED TOMOGRAPHY PREDICTS 10-YEAR MORTALITY IN INTERSTITIAL LUNG DISEASE RELATED TO SYSTEMIC SCLEROSI 119
Pulmonary Arterial Hypertension Incidence in Patients With Systemic Sclerosis Treated With Bosentan for Digital Ulcers: Evidence From the SPRING-SIR Registry. 113
Significant nailfold capillary loss and late capillaroscopic pattern are associated with pulmonary arterial hypertension in systemic sclerosis 108
The importance of body image and aesthetic medicine in systemic sclerosis 106
Prevalence and clinical relevance of digital ulcers in systemic sclerosis patients from the real-life: the experience of the SPRING Registry of the Italian Society for Rheumatology 105
First-line diagnostic tests to intercept primary heart involvement in systemic sclerosis: Clinical associations from the SPRING-SIR registry 103
Totale 21.802
Categoria #
all - tutte 89.860
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 89.860


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.479 0 64 109 127 75 130 45 108 175 136 326 184
2022/20231.671 216 207 116 147 205 210 69 151 220 25 53 52
2023/20241.162 42 69 52 168 204 91 91 111 31 40 98 165
2024/20254.633 139 77 91 311 851 734 369 268 532 215 413 633
2025/20269.328 618 317 633 1.104 1.366 622 1.130 435 853 890 816 544
2026/2027866 326 540 0 0 0 0 0 0 0 0 0 0
Totale 22.677